Salmeterol: profile and news

GSK Receives Positive Opinion From CHMP on Seretide (Salmeterol ... May 3, 2006
...received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) on dosing of Seretide™ (salmeterol/fluticasone propionate ... - DG News

Don’t panic if your asthma worsens over your lifetime May 13, 2006
Of the medications you mentioned, only Advair (fluticasone/salmeterol combination inhaler), which contains an inhaled corticosteroid, is an asthma medication. ... - Fort Wayne Journal Gazette,

Kos and SkyePharma Sign Exclusive License Agreement for the ... May 7, 2006
Bycontrast salmeterol, the bronchodilator used in GlaxoSmithKline'sAdvair(R)/Seretide(R), also provides 12 hours of bronchodilation, butneeds up to 30 minutes ... - Finanzen.net,

Asthmatx: a New Approach to Asthma Apr 19, 2006
...consists of relatively high doses of inhaled corticosteroids (ICS) in combination with a long-acting beta-2 agonist (LABA) such as salmeterol or formoterol. ... - International News Service,

GlaxoSmithKline gets positive EU opinion on Seretide dosing May 3, 2006
...has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) on dosing of Seretide (salmeterol/fluticasone propionate ... - MarketWatch

SkyePharma and Kos Announce Exclusive Licence Agreement for ... May 7, 2006
By contrast salmeterol, the bronchodilator used in GlaxoSmithKline's Advair/Seretide, also provides 12 hours of bronchodilation but needs up to 30 minutes ... - Yahoo! News (press release)

SkyePharma seals Flutiform pact with Kos May 8, 2006
Flutiform will compete in the US marketplace with GlaxoSmithKline's Symbicort (salmeterol and fluticasone), which shrugged off a black box safety warning to ... - Pharma Times (subscription),

Viapaed Study In Children And Adolescents With Asthma Apr 21, 2006
Children who remain symptomatic while inhaling 100 µg fluticasone (FP) twice daily shall be randomised to receive the salmeterol/ fluticasone combination ... - Community Dispatch (press release)

‘Patients can lead asthma-free lives’ Apr 29, 2006
Patients treated with Seretide (a new combination therapy with Fluticasone propionate and Salmeterol combined in one inhaler) showed a remarkable improvement ... - Daily Times,

First Quarter Report 2006: Schwarz Pharma with a Good Start Apr 25, 2006
This growth is mainly attributable to sales of the antiasthmatic drug Atmadisc® (fluticasone/ salmeterol), which was up 11.7% to €11.8 million and the ... - PharmaLive.com (press release),

Asthma Treatment, Finally An Effective Drug-free Alternative Apr 19, 2006
Drug company GlaxoSmithKline's study of Salmeterol, the medication used in Advair and another Glaxo asthma product, Serevent appeared to trigger fatal attacks ... - Emediawire (press release),

SkyePharma PLC - Preliminary Results Announcement for the Year ... Apr 19, 2006
By contrast salmeterol, the bronchodilator used in GlaxoSmithKline's Advair/Seretide, is also a twice-daily product but has the drawback of needing 30-45 ... - PR Newswire (press release),

GSK sees better-than-expected 1Q Apr 28, 2006
...up 44% to £366 million, and another pleasing performance from its number one asthma offering Seretide/Advair (fluticasone plus salmeterol), which rose 12% to ... - Pharma Times (subscription),

COPD patients show reduced bronchial inflammation after ... Apr 20, 2006
The combination of two existing clinical treatments, salmeterol and fluticasone propionate, can significantly reduce inflammatory cells in the airways of ... - Therapeutics Daily (subscription) (press release),

Other information

Indication
For the treatment of Asthma and chronic obstructive pulmonary disease (COPD).

Pharmacology
Salmeterol, a highly selective beta(2)-agonist, is used to treat asthma and to prevent bronchospasm in patients with reversible obstructive airway disease.

Mechanism Of Action
Salmeterol's long, lipophilic side chain binds to exosites near beta(2)-receptors in the lungs and on bronchiolar smooth muscle, allowing the active portion of the molecule to remain at the receptor site, continually binding and releasing. Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.

Drug Category
Bronchodilator Agents; Sympathomimetic; Adrenergic beta-Agonists;

Brand Names/Synonyms
Aeromax; Arial; Astmerole; CHEMBANK1801; SEREVENT; Salmetedur; Salmeterol; Salmeterol Xinafoate; Salmeterol [Usan:Ban:Inn]; Salmeterolum [Latin]; Serevent; [Usan:Ban:Inn]

Dosage Forms
METERED-DOSE (AEROSOL); POWDER

Absorption
Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses (50 mcg of salmeterol inhalation powder twice daily). Following chronic administration of an inhaled dose of 50 mcg of salmeterol inhalation powder twice daily, salmeterol was detected in plasma within 5 to 45 minutes in 7 patients with asthma; plasma concentrations were very low, with mean peak concentrations of 167 pg/mL at 20 minutes and no accumulation with repeated doses.

Interactions